公开(公告)号：US20180230140A1

公开(公告)日：2018-08-16

申请号：US15320608

申请日：2015-06-24

Applicant: BASF SE

Inventor： Martin VIERTELHAUS ,  Tiziana CHIODO ,  Beate SALVADOR ,  Marcus VOSSEN ,  Andreas HAFNER ,  Tobias HINTERMANN ,  Martin SZELAGIEWICZ ,  Fritz BLATTER

IPC: C07D417/14 ,  C07C39/06 ,  C07C47/58 ,  A61P35/02

CPC classification number: C07D417/14 ,  A61P35/02 ,  C07B2200/13 ,  C07C39/06 ,  C07C47/58 ,  C07D417/12

Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.

公开(公告)号：US20210388014A1

公开(公告)日：2021-12-16

申请号：US17286474

申请日：2019-10-17

Applicant: BASF SE

Inventor： Michael PUHL ,  Sebastian WLOCH ,  Peter OEDMAN ,  Anne-Catrin LETZEL ,  Hartwing SCHROEDER ,  Jacek MALISZ ,  Daniel SEIBERT-LUDWIG ,  Emiel Jan KAPPERT ,  Chung Huan WONG ,  Michael BARROS GROSS ,  Martin VIERTELHAUS

IPC: C07H1/08 ,  C07H3/06

Abstract: The present invention relates to a method for obtaining crystalline 2′-fucosyllactose from a 2′-FL raw material, which contains 2′-FL as a main constituent and at least 0.5% by weight, frequently at least 1% by weight, in particular at least 2% by weight, more particularly at least 5% by weight, and especially at least 8% by weight,based on the total amount of mono-and oligosaccharides in the raw material, of one or more mono- or oligosaccharides different from 2′-FL, where the method comprises a)providing a solution of the 2′-FL raw material in water, which does not contain more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents, based on the total amount of water; b) effecting the crystallization of 2′-FL from the solution provided in step a) by inducing conditions of a controlled super saturation in the solution; and c) separating crystalline 2′-FL from the mother liquor, and where during controlled supersaturation in step b) not more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents are present, based on the total amount of water present during step b).

公开(公告)号：US20210137112A1

公开(公告)日：2021-05-13

申请号：US16497938

申请日：2018-03-27

Applicant: BASF SE

Inventor： Martin VIERTELHAUS ,  Dennis KOULELIS ,  Tobias SEISER ,  Cyrill ZAGAR ,  Gregory ARMEL ,  Ulrich STEINBRENNER ,  Liliana PARRA RAPADO ,  Saskia PAEHLER ,  Laetitia SOUILLART

IPC: A01N43/54 ,  C07D401/12 ,  A01N25/14 ,  A01N61/00 ,  A01N25/32

Abstract: The present invention relates to crystalline forms of ethyl[3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyl-oxy]acetate (CAS 353292-31-6), herein after also referred to as “compound of formula (I)”.
The invention also relates to a process for the production of these crystalline forms, formulations for plant protection and herbicidal compositions which contain one of these crystalline forms

公开(公告)号：US20160303143A1

公开(公告)日：2016-10-20

申请号：US15103146

申请日：2014-12-09

Applicant: BASF SE

Inventor： Tiziana CHIODO ,  Beate SALVADOR ,  Marcus VOSSEN ,  Andreas HAFNER ,  Tobias HINTERMANN ,  Martin SZELAGIEWICZ ,  Fritz BLATTER ,  Martin VIERTELHAUS ,  Walter WEISHAAR

IPC: A61K31/58 ,  C07J43/00

CPC classification number: A61K31/58 ,  A61K9/14 ,  C07B2200/13 ,  C07J43/003

Abstract: Combinations of (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Abstract translation: （3β）-17-（吡啶-3-基）雄甾-5,16-二烯-3-基乙酸酯（醋酸阿比酮酮）与酸性物质如柠檬酸，抗坏血酸，甲基-4-羟基苯甲酸酯，糖精 ，香草酸，己二酸，马来酸，苹果酸，酒石酸可用作药物制剂，并显示出改善的性质，例如水溶性和溶解动力学，特别是以共晶体形式或与合适的酸的组合。